Star Therapeutics, a late clinical-stage biotechnology company discovering and developing best-in-class antibodies for ...

On March 18, 2016, the National Academies of Science, Engineering, and Medicine (The Academies) announced the appointment of its provisional committee on "Future Biotechnology Products and ...

Initial durability data shows all patients (100%) who completed the Maintenance Treatment Phase (MTP) sustained CRs in the treated area for at least 12 months as of the data cutoff date -- ...

On Monday, April 24, The Biotechnology Study Center of NYU School of Medicine will hold its annual awards symposium to honor three outstanding pioneers in neurobiology and cognition. The Dart/NYU ...

Granata Bio Corporation, a biotechnology company advancing innovative reproductive health solutions, announced strong ...

NEW YORK -- Investors accurately forecasted the rebound of the biotechnology industry, but underestimated the degree to which positive clinical trial data would drive the sector higher, according to ...

Scientists have found that common foods can contain hidden contaminants formed during cooking or through environmental ...

Unity Biotechnology, Inc. (NASDAQ:UBX) stock plummeted on Monday after the company released results from its latest study. The Phase 2b ASPIRE clinical trial of intravitreal UBX1325 involed patients ...

CRANBURY, N.J.--(BUSINESS WIRE)--Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, today announced the dosing of the first patient ...

Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was non-inferior to aflibercept at week 24 (>90% ...

MAIA Biotechnology, Inc. ( ($MAIA) ) has shared an announcement. On November 20, 2025, MAIA Biotechnology announced that its CEO, Vlad Vitoc, ...

UNITY Biotechnology, Inc. has announced that it will present data from its ASPIRE Phase 2B study on its senolytic candidate, UBX1325, targeting diabetic macular edema at the upcoming ARVO 2025 Annual ...